UPCOMING CONFERENCES

BEBPA conferences include 2-3 days of presentations, workshops and round-table discussions on topics of current interest to the analytical biopharmaceutical community. It is hoped that these presentations and discussions will provide topics for future white paper working groups.

Please come and participate in the next BEBPA conference. This is an opportunity to shape the future of the association and to ensure it addresses the issues of concern to you.

We are currently accepting Topics and Abstracts for our 2019 conferences.

Please click on the button below to go to our Abstracts Page and submit an abstract for review!

Please click on the button below to go to our Topics Page and suggest a topic for a future BEBPA conference!

3rd Annual US Bioassay Conference

March 13-15, 2019. San Pedro, CA, USA. Crowne Plaza LA Harbor Hotel.
More information coming soon!

Preliminary Topics:

  • Bioassay Lifecycle
  • Bioassays for Product Release/ Characterization
  • Statistical Analysis: Why and How Much?
  • Improving Assays Using Technology
  • Determining Similarity of Reference Vs. Test Sample Dose-Response Curve
  • Assay Replacement
  • Interactive Survey
  • Handling Outliers for Bioassay’s
  • Product Specific Bioassays
  • Product Characterization with Biological Assays

7th Annual HCP Conference

May 15-17, 2019, San Pedro, CA, USA. Crowne Plaza LA Harbor Hotel
More information coming soon!

Preliminary Topics:

  • Generation of Immunoassay Reagents That Display Greater Coverage
  • MS Identification of HCPs: Impact of Data Analysis Methods
  • Lifecycle Management of Critical Reagents
  • Safety Assessment for HCPs
  • Detection of HCPs in Commercial Products
  • Detection and Quantification of Lipases in Drug Substance
  • Development of Methods for Gene Therapy Products
  • The Impact of Bioprocess Improvements on HCP Profiles and Detection (e.g.; cell line engineering, continuous manufacturing)
  • The Latest Input from Health Authorities on How to Manage HCP Data in Regulatory Filings
  • Generation of high coverage anti-HCP antibodies.
  • Setting HCP specifications.
  • Risk assessment case studies.
  • HCPs for non-antibodies.
  • Cell culture and purification perspectives on HCP production and monitoring.
  • Improved MS technologies for HCP identification and control.
  • HCP activities that impact product quality or stability.
  • Real-life examples on reagent lifecycle management.

12th Annual EUR Bioassay Conference

September 25-27, 2019, Prague, Czechia
Hotel International Prague
More information coming soon!

  • 384-well plate assay development case studies
  • Product reference programs for potency assays
  • Update on USP
  • FDA regulatory update
  • Assessing similarity of reference vs. test
  • Case studies

— Development
— Product specific
— Validation

  • Comparability studies
  • Selecting an appropriate bioassay
  • Product specific potency assays

— Immuno-oncology products
— Gene and cell therapies
— rDNA protein products
— Vaccines

  • Life cycle approach to bioassays
  • Implementing new technology into your bioassay
  • Use of statistical tools for bioassays

— DOE
— SPC